Tenecteplase

Main Article Content

Chanthaporn Imbumroong

Abstract

-

Keywords

Article Details

Section
ยาน่ารู้ (Interesting Drugs)

References

1. Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354(9180):716-22.
2. Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, et al. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of a single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. Am Heart J 2003;146:27-32.
3. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358(9282):605-13.
4. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction. Circulation 2003;108:135-42.
5. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367(9510):569-78.
6. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013;368:1379-87.
7. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-77.
8. Vanscoy GJ, Rihn TL, Koerner PH. Tenecteplase: innovative fibrinolysis for ST-segment elevation myocardial infarction (STEMI). P&T® [Internet]. 2003 [cited 2019 Mar 19]; 28 (1): 20-30. Available from:
https://pdfs.semanticscholar.org/e1fa/f1a08df2ef2e31444dd1e8546da5aa504cfc.pdf
9. Metalyse 8,000 units. [Internet]. 2006 Feb 23 [ update 2017 Oct 25; cited 2019 Mar 19]. Available from: https://www.medicines.org.uk/emc/product/3012/smpc
10. Metalyse [Internet]. 2019 [cited 2019 Mar 19]. Available from: https://www.metalyse.com/metalyse
11. Michael M. Tenecteplase (TNKase™): A Clinical Review. Pharmacotherapy Update [Internet]. 2001 [cited 2019 Mar 19]; 4(1): Available from: https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/JanFeb2001/Tenecteplase.htm
12. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013
ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation [Internet]. 2013 [cited 2019 Mar19];127(4): e362-425. Available from: https://www.ahajournals.org/doi/pdf/10.1161/CIR.0b013e3182742cf6
13. Tenecteplase [Internet] 2005 June 13 [ update 2019 Feb 12; cited 2019 Mar 19]. Available from: https://www.drugbank.ca/drugs/DB00031
14. Tenecteplase [Internet] 2000 [update 2019 Feb 4; cited 2019 Mar19]. Available from:
https://www.drugs.com/ppa/Tenecteplase.html
15. Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003;89:1358–62.
16. Sitthisuk S.. Guideline for ischemic heart disease 2014. 2nd ed. Bangkok: 2019 The Heart Association of Thailand Under The Royal Patronage of H.M. The King; 2014. 72 p.